Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia

Viralkumar Patel, Michael J. Keating, William G. Wierda, Varsha Gandhi

Research output: Contribution to journal › Letter › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia'. Together they form a unique fingerprint.